Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLGL Price/Volume Stats
| Current price | $3.60 | 52-week high | $6.89 |
| Prev. close | $3.34 | 52-week low | $3.10 |
| Day low | $3.32 | Volume | 14,200 |
| Day high | $3.60 | Avg. volume | 14,450 |
| 50-day MA | $3.70 | Dividend yield | N/A |
| 200-day MA | $4.63 | Market Cap | 83.26M |
SLGL Stock Price Chart Interactive Chart >
SLGL Stock Summary
- With a year-over-year growth in debt of -51.48%, SOL-GEL TECHNOLOGIES LTD's debt growth rate surpasses just 5.15% of about US stocks.
- Over the past twelve months, SLGL has reported earnings growth of -563.3%, putting it ahead of just 3.31% of US stocks in our set.
- Revenue growth over the past 12 months for SOL-GEL TECHNOLOGIES LTD comes in at -87.58%, a number that bests just 1.69% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to SOL-GEL TECHNOLOGIES LTD, a group of peers worth examining would be VBLT, IMGN, BNTC, FULC, and PTN.
- SLGL's SEC filings can be seen here. And to visit SOL-GEL TECHNOLOGIES LTD's official web site, go to www.sol-gel.com.
SLGL Valuation Summary
- In comparison to the median Healthcare stock, SLGL's price/sales ratio is 350% higher, now standing at 21.6.
- Over the past 64 months, SLGL's price/earnings ratio has gone up 5.4.
Below are key valuation metrics over time for SLGL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SLGL | 2023-05-01 | 21.6 | 2 | -5.6 | -4.0 |
| SLGL | 2023-04-28 | 21.4 | 2 | -5.6 | -3.9 |
| SLGL | 2023-04-27 | 21.3 | 2 | -5.5 | -3.9 |
| SLGL | 2023-04-26 | 21.7 | 2 | -5.7 | -4.0 |
| SLGL | 2023-04-25 | 21.9 | 2 | -5.7 | -4.1 |
| SLGL | 2023-04-24 | 21.6 | 2 | -5.6 | -4.0 |
SLGL Price Target
For more insight on analysts targets of SLGL, see our SLGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.25 | Average Broker Recommendation | 1.25 (Strong Buy) |
Sol-Gel Technologies Ltd. (SLGL) Company Bio
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
Latest SLGL News From Around the Web
Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue EstimatesSol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -86.36% and 51.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePositive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NE |
Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
‘Load Up,’ Says Raymond James About These 3 ‘Strong Buy’ StocksThe last few weeks have been rocky, with the collapse of Silicon Valley Bank, and the crypto-heavy Silvergate and Signature banks, dominating the headlines. For a short time, it seemed that the contagion would spread to the global financial giants. Now, however, it appears that we’ve managed to avoid a true banking crisis – and Raymond James’ chief investment officer Larry Adam has pointed out several reasons why. For starters, Adam notes that Credit Suisse, despite its troubles, found a way out |
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceNESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023. Presentation Information Event:H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceDate:Thursday, March 30th, 2023Format:Live Com |
SLGL Price Returns
| 1-mo | 0.28% |
| 3-mo | -17.53% |
| 6-mo | -23.89% |
| 1-year | -43.11% |
| 3-year | -53.37% |
| 5-year | -61.66% |
| YTD | -21.05% |
| 2022 | -38.38% |
| 2021 | -24.41% |
| 2020 | -42.92% |
| 2019 | 184.88% |
| 2018 | N/A |
Continue Researching SLGL
Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...